Partnering for New Findings
Clinical trials are a major step to translate pharmacological potential into clinical safety and efficacy
NeuroAiD™, our first product for post-stroke recovery, was commercialized for the first time in Singapore in 2006. It is today available in over 35 countries in South-East Asia, Europe, Africa and Middle-East.
The research on NeuroAiD™ is still very active in post-stroke recover but also in new indications for NeuroAiD™ such as traumatic brain injuries and neurodegenerative diseases (i.e. Alzheimer disease). On average, 4 to 5 papers are published each year by independent researchers, and communicated in international conferences on stroke.
The research on NeuroAiD™ is still very active in post-stroke recover but also in new indications for NeuroAiD™ such as traumatic brain injuries and neurodegenerative diseases (i.e. Alzheimer disease). On average, 4 to 5 papers are published each year by independent researchers, and presented in international conferences on stroke.
